US Patent Issued to Ablynx, Sanofi on Jan. 20 for "Polypeptides comprising immunoglobulin single variable domains targeting TNFAlpha and IL-23" (Belgian, German Inventors)

ALEXANDRIA, Va., Jan. 20 -- United States Patent no. 12,528,860, issued on Jan. 20, was assigned to Ablynx NV (Ghent-Zwijnaarde, Belgium) and Sanofi (Paris).

"Polypeptides comprising immunoglobulin single variable domains targeting TNFAlpha and IL-23" was invented by Heidi Rommelaere (Ghent, Belgium), Christian Asbrand (Frankfurt Am Main, Germany), Ann Brige (Ertvelde, Belgium), Sigrid Cornelis (St. Martens-Latem, Belgium) and Eric Lorent (Zwijnaarde, Belgium).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present technology aims at providing a novel type of drug. Specifically, the present technology provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characteri...